AITSU is a startup that commercialises ultrasound guided intralymphatic Immunotherapy as a disruptive treatment for grass pollen allergy. To improve the quality of the injections, we want to build software that can identify lymph nodes and the needle in real time and guide the needle to the optimal site for the intralymphatic injection of medicine.

Only 7.9% of new medicin is approved for phase 1 clinical programs - life saving cures are being scrapped because of poor reproducibility. Today, researchers designing complex in vitro and in vivo experiments jump between many tools that do not talk to each other. Protocols are written in free text, naming is inconsistent, raw data is scattered across drives, and inventory and cell banks are tracked separately. This makes it hard to reproduce experiments, compare results across projects, trace which cell material went into which batch, and satisfy regulatory expectations. Small and mid-sized labs often cannot afford enterprise platforms like Benchling or Dotmatics, so they manually glue everything together and rarely get to use advanced analytics or AI. BioPilot solves this by standardising the full early-to-in-vivo CTR pipeline in one product. Users can register and template in vitro experiments (differentiation, expansion, cryopreservation, device testing, etc.) and in vivo studies (animals, groups, dosing, housing, ethics documents) using fixed ontologies. This gives every experiment a structured schema and a precise schedule of readouts, barcodes and data types to collect. Raw data (FACS, scRNA-seq, imaging, counters, bioreactor logs, etc.) is then automatically linked back to the right experiment, condition and sample. On top of this, BioPilot offers: • Inventory and cell bank tracking that makes it trivial to trace which vial, edit or expansion batch was used where. • Live bioreactor monitoring with alarms (email / phone) to prevent losing expensive batches. • A growing library of free analytical tools, including automated FACS gating, scRNA-seq pipelines and image analysis that can feed results straight back into the experiment records. • A global ontology service for vendors, instruments, cell lines, species and process terms, with a roadmap for a public API. Because everything is structured and queryable, BioPilot makes it much easier to compare experiments, run Bayesian optimisation on process parameters, and let AI suggest next-step experiments. The pricing is kept aggressively low (free tier plus a simple paid tier based on storage), so smaller biotech and academic groups can access capabilities that are normally reserved for organisations with large software budgets. In short, BioPilot aims to become the operating system for cell therapy R&D: a single, affordable platform where experiments are planned, executed, monitored and analysed in a way that is standardised enough for automation and flexible enough for real-world biology.

Tendavo is an AI-driven growth partner that helps small and medium-sized companies win public procurements. We are tackling one of the world's largest but most neglected markets: public procurement, worth 15% of the OECD countries' GDP. We have proven product-market fit, strong profitability, and a founding team from McKinsey, Kivra, and Handelsbanken. We are also part of the SSE Business Lab, the incubator behind companies like Klarna, Voi, and Legora.

At HeyCompanion, we’re transforming the way people interact with streaming content. Viewers today constantly reach for their phones while watching TV — 86% use a second screen, and 69% say they want instant answers about what they see. Every time they leave to search, streaming platforms lose attention, data, and potential revenue. We solve this by turning distraction into engagement. HeyCompanion is an AI-powered discovery layer that lets viewers instantly explore and act on what’s on-screen — actors, outfits, locations, and products — all in real time, without leaving the story. Our technology bridges the gap between attention and discovery, giving viewers interactive context while helping streaming platforms reduce churn, increase retention, and unlock new commerce opportunities. By analyzing what people watch and what they discover, we generate unique behavioral insights that help platforms understand audience intent — something traditional analytics can’t capture.

Multi-carrier shipping software Aigol is a multi-carrier transportation management solution designed for the needs of road freight and parcel shipping. The platform supports the full shipment lifecycle, including booking, label and document generation, consolidation, and end-to-end tracking. By centralizing connections to multiple carriers in a single system, Aigol provides operational flexibility and ensures consistent handling of shipments across different logistics partners. Automation capabilities reduce manual work, enhance planning efficiency, and improve cost control. Aigol enables organizations to manage their logistics processes with reliability, transparency, and scalability.

This is the official ITU Student Council profile on The Hub. This account was created to support student organisations at ITU in promoting job opportunities and organisational roles on The Hub. All posts shared through this profile are published on behalf of ITU’s student organisations and are not affiliated with the ITU Student Council itself.

BOLD. disruptive. AMBITIOUS. MEMORABLE. GORILLA AGENCY is an internationally recognized award winning creative agency with over 100+ awards, honors and nominations at 20+ award programs globally. We focus on communicating complex messages, social good and impact campaigns. Creativity can change the world. We know because we've done it. We want to bridge the gap between profit and purpose, and help facilitate a positive change through advertising. We work with brands and organisations that want to facilitate change. Those that aren't afraid of using their voice and engage in tough conversations. Our campaigns have questioned the the status quo, challenged what's possible for an agency to do and was founded on the principle that creating positive change is more important than making profit.

Across cities, countless square meters are sitting unused – basements, garages, parking spots, and storage rooms. At the same time, people are struggling to find space: the driver without a parking option, the student with too many moving boxes, or the small business in need of affordable storage nearby. Today, the market is fragmented. On one side, people rely on Facebook groups and classifieds – messy, insecure, and inefficient. On the other side, traditional self-storage companies offer standardized units, but often at high prices and in inconvenient locations. What’s missing is a trusted, flexible platform that brings everything together – where you can easily find, rent, and share all kinds of space, from a neighbor’s garage to professional self-storage, in one seamless experience. That’s the gap we’re here to fill with Nearby.

Solid IO is developing a test that shows in advance whether immuno-oncology (IO) drugs will work for each cancer patient, helping doctors avoid trial-and-error and giving more patients access to these promising medicines. IO drugs are transforming cancer care, but they don’t work for everyone. Today, most patients tat receive these treatments don't benefit. Valuable time and resources are lost, and side effects and emotional stress can be heavy. This problem touches millions of people worldwide, frustrates doctors, and slows down the development of new IO drugs. Our solution is a test that mimics a patient’s cancer and immune system outside the body. With it, doctors and researchers can see how that patient reacts to IO medicines before starting treatment. This means patients get a more effective plan right away, and pharma and biotech companies can design smarter, faster trials for new IO drugs and combinations. We started Solid IO because we believe cancer patients deserve more than guesswork. In our work we saw how life-changing IO medicines can be, but also how devastating it is when they fail. That inspired us to create a way to bring more certainty, speed, and hope into cancer care.

Nuvve powers the future of flexible energy by turning electric vehicles (EV), batteries, buildings, and distributed assets into dynamic grid resources. At the core is Nuvve’s advanced platform for vehicle-to-grid (V2G) and intelligent energy management, orchestrating real-time bidirectional charging, load optimization, and grid services. By harnessing an ecosystem of electrification partners, fleets, stationary storage, and smart EV chargers, Nuvve helps utilities and communities unlock flexibility at scale — enhancing reliability, accelerating electrification, and lowering costs. Nuvve enables a clean energy future where mobility, buildings, and infrastructure work together to support a more resilient, sustainable, and equitable grid. Headquartered in San Diego, California, Nuvve operates globally and online at nuvve.com

Revolutionising diagnostics through innovation. We are at the forefront of healthcare transformation, developing portable blood test devices that deliver rapid and reliable results. Our mission is to optimise the healthcare system, making it more accessible, efficient, and patient-centric for a healthier tomorrow.

At Tidypay, we are on a mission to be the undisputed choice of Payments for Point of Sale (POS) vendors in Europe. We are building the future of card payments with Android based payment terminals and SoftPOS. With Tidypay’s unique payment solution our customers can easily bolt-on payments to their POS offer. The result is a game changer for the merchant: All-in-one terminals with POS and payments software. One provider, one device and all the benefits: reduced costs, increased efficiency and convenience.

GLAZE Technologies turns raw data into “material intelligence.” Across energy, aerospace, and manufacturing, critical components can fail because decision-makers can’t see what’s happening inside their materials until it’s too late. Today they must choose between expensive lab testing or flying blind on the factory floor. We solve that gap with Carmen, our patented, real-time sensor platform that reveals a material’s composition, defects, and degradation at industrial speed and scale. Powered by breakthrough terahertz technology, Carmen spots micro-cracks in wind-turbine blades before they splinter, verifies satellite parts for the European Space Agency, and will soon help any production line certify quality without stopping the line. Why does it matter? Because better material insight means safer infrastructure, fewer recalls, less waste, and a faster transition to a sustainable, high-performance world. We’ve proven the tech in pilots with global consortia; now we’re scaling the business. and looking for bold minds to join the journey.

Meo.io is a RegTech platform based in Copenhagen that helps businesses—particularly in highly-regulated industries like law firms, private equity and capital management—streamline and automate their compliance workflows. It offers: KYC & KYB onboarding: document verification, risk assessment, multi-source identity checks. Ongoing compliance lifecycle: sanctions and PEP screening, adverse media monitoring, encrypted client communications, GDPR and AML oversight. Client-controlled data management: users securely store and share their own compliance data, reducing duplication and enhancing data ownership. Enterprise-grade security: built on Privacy‑by‑Design with AES‑256 encryption, ISO 27001 and ISAE 3000 certifications. Rebranded in June 2025, the new name Meo—to reflect “My/Mine” in Latin—reinforces the focus on individual data ownership and privacy control. In short, Meo.io is an all-in-one compliance hub for collecting, verifying, monitoring and sharing regulatory data—empowering firms to onboard faster, reduce risk, and stay compliant seamlessly.

No-code workflow tool for automating and chaining AI prompts. Features a drag-and-drop builder, model flexibility, one-click sharing as apps, and reusable automation templates The biggest issue with working with prompt chaining in ChatGPT, Gemini, or Claude is that the increased chat length makes the AI begin to hallucinate. For example, if you want to prompt the AI to write an article, it's almost impossible for it not to begin to make slop and ignore/forget your instructions. For most people, this tool will not be that interesting. Chat interfaces are king for quick questions. But if you've struggled with generating consistent, high quality, content using ChatGPT, then you know exactly the problem this solves.